OncoMatch/Clinical Trials/NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Is NCT05595447 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Brentuximab Vedotin 50 MG [Adcetris] for hodgkin lymphoma.
Treatment: Brentuximab Vedotin 50 MG [Adcetris] — The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: cytotoxic chemotherapy (ABVD)
Relapsed/refractory Hodgkin lymphoma to ABVD
Lab requirements
Kidney function
serum creatinine ≤ 1.5x uln or glomerular filtration rate > 50ml/min
Liver function
total serum bilirubin ≤ 1.5 x uln; ast ≤ 3.0 x uln; alt ≤ 3.0 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify